A citation-based method for searching scientific literature

C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard, F Andrè, J S Reis-Filho. Ann Oncol 2019
Times Cited: 87







List of co-cited articles
732 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
894
63

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
359
49

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
174
47

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
160
44

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
116
44

Testing algorithm for identification of patients with TRK fusion cancer.
Frédérique Penault-Llorca, Erin R Rudzinski, Antonia R Sepulveda. J Clin Pathol 2019
56
60

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
229
36

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
283
35

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
222
28

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco,[...]. Lancet Oncol 2018
204
27


The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
480
22


High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
117
22

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
133
22

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.
Anna F Farago, Martin S Taylor, Robert C Doebele, Viola W Zhu, Shivaani Kummar, Alexander I Spira, Theresa A Boyle, Eric B Haura, Maria E Arcila, Ryma Benayed,[...]. JCO Precis Oncol 2018
73
26

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
136
20

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
365
20

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
169
20

A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.
S R Knezevich, D E McFadden, W Tao, J F Lim, P H Sorensen. Nat Genet 1998
523
20

Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
Alena Skálová, Tomas Vanecek, Radek Sima, Jan Laco, Ilan Weinreb, Bayardo Perez-Ordonez, Ivo Starek, Marie Geierova, Roderrick H W Simpson, Fabricio Passador-Santos,[...]. Am J Surg Pathol 2010
492
18

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Erin R Rudzinski, Christina M Lockwood, Bradley A Stohr, Sara O Vargas, Rachel Sheridan, Jennifer O Black, Veena Rajaram, Theodore W Laetsch, Jessica L Davis. Am J Surg Pathol 2018
86
18

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, David Huntsman, Calvin D Roskelley, Natalya Melnyk, Joan A Mathers, Laurence Becker, Fatima Carneiro, Nicol MacPherson, Doug Horsman,[...]. Cancer Cell 2002
528
18

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Ryosuke Okamura, Amélie Boichard, Shumei Kato, Jason K Sicklick, Lyudmila Bazhenova, Razelle Kurzrock. JCO Precis Oncol 2018
105
17

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.
Robert C Doebele, Lara E Davis, Aria Vaishnavi, Anh T Le, Adriana Estrada-Bernal, Stephen Keysar, Antonio Jimeno, Marileila Varella-Garcia, Dara L Aisner, Yali Li,[...]. Cancer Discov 2015
210
17


Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
347
17

Identifying patients with NTRK fusion cancer.
J P Solomon, R Benayed, J F Hechtman, M Ladanyi. Ann Oncol 2019
51
29

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
55
25

Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Emiliano Cocco, Jamal Benhamida, Sumit Middha, Ahmet Zehir, Kerry Mullaney, Jinru Shia, Rona Yaeger, Liying Zhang, Donna Wong, Liliana Villafania,[...]. Cancer Res 2019
50
28

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Sarah Chiang, Paolo Cotzia, David M Hyman, Alexander Drilon, William D Tap, Lei Zhang, Jaclyn F Hechtman, Denise Frosina, Achim A Jungbluth, Rajmohan Murali,[...]. Am J Surg Pathol 2018
87
16

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Shivaani Kummar, Ulrik N Lassen. Target Oncol 2018
39
33

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
14

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, Jeeyun Lee, Sabine Tejpar, Andrea Sartore-Bianchi, Jaclyn F Hechtman, Jason Christiansen, Luca Novara, Niall Tebbutt,[...]. J Natl Cancer Inst 2017
98
14

Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
Nicole Pfarr, Martina Kirchner, Ulrich Lehmann, Jonas Leichsenring, Sabine Merkelbach-Bruse, Julia Glade, Michael Hummel, Fabian Stögbauer, Annika Lehmann, Marcel Trautmann,[...]. Genes Chromosomes Cancer 2020
24
54

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
13


TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Catherine M Albert, Jessica L Davis, Noah Federman, Michela Casanova, Theodore W Laetsch. J Clin Oncol 2019
33
33

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Anna F Farago, Long P Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M Bauer, Stephen V Liu, Sai-Hong I Ou, David Jackman,[...]. J Thorac Oncol 2015
143
12

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
464
12

Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing.
Danielle A Murphy, Heather A Ely, Robert Shoemaker, Aaron Boomer, Brady P Culver, Ian Hoskins, Josh D Haimes, Ryan D Walters, Diane Fernandez, Joshua A Stahl,[...]. Appl Immunohistochem Mol Morphol 2017
46
23

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
159
12


Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Alanna J Church, Monica L Calicchio, Valentina Nardi, Alena Skalova, Andre Pinto, Deborah A Dillon, Carmen R Gomez-Fernandez, Namitha Manoj, Josh D Haimes, Joshua A Stahl,[...]. Mod Pathol 2018
60
18


The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
Steven G DuBois, Theodore W Laetsch, Noah Federman, Brian K Turpin, Catherine M Albert, Ramamoorthy Nagasubramanian, Megan E Anderson, Jessica L Davis, Hope E Qamoos, Mark E Reynolds,[...]. Cancer 2018
57
17


Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Kurtis D Davies, Anh T Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L Jones, Marileila Varella-Garcia, Dara L Aisner, Robert C Doebele. J Thorac Oncol 2018
64
15

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina De Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texido, Anna Degrassi,[...]. Mol Cancer Ther 2016
140
11

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Eileen Shi, Juliann Chmielecki, Chih-Min Tang, Kai Wang, Michael C Heinrich, Guhyun Kang, Christopher L Corless, David Hong, Katherine E Fero, James D Murphy,[...]. J Transl Med 2016
93
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.